참고문헌
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29. https://doi.org/10.3322/caac.21254
- Bagshaw MA, Kaplan HS, Sagerman RH. Linear accelerator supervoltage radiotherapy. VII. Carcinoma of the prostate. Radiology 1965;85:121-9. https://doi.org/10.1148/85.1.121
- DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014;64:252-71. https://doi.org/10.3322/caac.21235
- Leibel SA, Zelefsky MJ, Kutcher GJ, et al. The biological basis and clinical application of three-dimensional conformal external beam radiation therapy in carcinoma of the prostate. Semin Oncol 1994;21:580-97.
- Ling CC, Burman C, Chui CS, et al. Conformal radiation treatment of prostate cancer using inversely-planned intensity-modulated photon beams produced with dynamic multileaf collimation. Int J Radiat Oncol Biol Phys 1996;35:721-30.
- Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005;294:1233-9. https://doi.org/10.1001/jama.294.10.1233
- National Comprehensive Cancer Network. NCCN Guidelines: prostate cancer version 3, 2016 [Internet]. Fort Washington, PA: National Comprehensive Cancer Network; c2017 [cited at 2017 May 15]. Available from: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
- Xu N, Rossi PJ, Jani AB. Toxicity analysis of dose escalation from 75.6 Gy to 81.0 Gy in prostate cancer. Am J Clin Oncol 2011;34:11-5. https://doi.org/10.1097/COC.0b013e3181cae8c6
- Williams MV, Denekamp J, Fowler JF. A review of alpha/beta ratios for experimental tumors: implications for clinical studies of altered fractionation. Int J Radiat Oncol Biol Phys 1985;11:87-96. https://doi.org/10.1016/0360-3016(85)90366-9
- Nahum AE. The radiobiology of hypofractionation. Clin Oncol (R Coll Radiol) 2015;27:260-9. https://doi.org/10.1016/j.clon.2015.02.001
- Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 2007;67:1099-105. https://doi.org/10.1016/j.ijrobp.2006.10.050
- King CR, Freeman D, Kaplan I, et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol 2013;109:217-21. https://doi.org/10.1016/j.radonc.2013.08.030
- Bolzicco G, Favretto MS, Satariano N, Scremin E, Tambone C, Tasca A. A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy. BMC Urol 2013;13:49. https://doi.org/10.1186/1471-2490-13-49
- Buyyounouski MK, Price RA Jr, Harris EE, et al. Stereotactic body radiotherapy for primary management of early-stage, low- to intermediate-risk prostate cancer: report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee. Int J Radiat Oncol Biol Phys 2010;76:1297-304. https://doi.org/10.1016/j.ijrobp.2009.09.078
- Kavanagh BD, Timmerman RD, Benedict SH, et al. How should we describe the radiobiologic effect of extracranial stereotactic radiosurgery: equivalent uniform dose or tumor control probability? Med Phys 2003;30:321-4. https://doi.org/10.1118/1.1543571
- Lischalk JW, Kaplan ID, Collins SP. Stereotactic body radiation therapy for localized prostate cancer. Cancer J 2016;22:307-13. https://doi.org/10.1097/PPO.0000000000000209
- Fowler JF. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol 2005;44:265-76. https://doi.org/10.1080/02841860410002824
- Duchesne GM, Peters LJ. What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-doserate brachytherapy. Int J Radiat Oncol Biol Phys 1999;44:747-8. https://doi.org/10.1016/S0360-3016(99)00024-3
- Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, noninferiority, phase 3 CHHiP trial. Lancet Oncol 2016;17:1047-60. https://doi.org/10.1016/S1470-2045(16)30102-4
- Wilkins A, Mossop H, Syndikus I, et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, noninferiority, phase 3 CHHiP trial. Lancet Oncol 2015;16:1605-16. https://doi.org/10.1016/S1470-2045(15)00280-6
- Incrocci L, Wortel RC, Alemayehu WG, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2016;17:1061-9. https://doi.org/10.1016/S1470-2045(16)30070-5
- Aluwini S, Pos F, Schimmel E, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncol 2016;17:464-74. https://doi.org/10.1016/S1470-2045(15)00567-7
- Halpern JA, Sedrakyan A, Hsu WC, et al. Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer. Cancer 2016;122:2496-504. https://doi.org/10.1002/cncr.30101
- Hardy D, Liu CC, Xia R, et al. Racial disparities and treatment trends in a large cohort of elderly black and white patients with nonsmall cell lung cancer. Cancer 2009;115:2199-211. https://doi.org/10.1002/cncr.24248
- Muralidhar V, Rose BS, Chen YW, Nezolosky MD, Nguyen PL. Association between travel distance and choice of treatment for prostate cancer: does geography reduce patient choice? Int J Radiat Oncol Biol Phys 2016;96:313-7. https://doi.org/10.1016/j.ijrobp.2016.05.022
- Xiang M, Nguyen PL. Significant association of brachytherapy boost with reduced prostate cancer-specific mortality in contemporary patients with localized, unfavorable-risk prostate cancer. Brachytherapy 2015;14:773-80. https://doi.org/10.1016/j.brachy.2015.09.004
- Muralidhar V, Xiang M, Orio PF 3rd, et al. Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer. J Contemp Brachytherapy 2016;8:1-6.
- Spratt DE, Zumsteg ZS, Ghadjar P, et al. Comparison of highdose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer. BJU Int 2014;114:360-7.
- Brown JM, Carlson DJ, Brenner DJ. The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved? Int J Radiat Oncol Biol Phys 2014;88:254-62. https://doi.org/10.1016/j.ijrobp.2013.07.022
- Song CW, Kim MS, Cho LC, Dusenbery K, Sperduto PW. Radiobiological basis of SBRT and SRS. Int J Clin Oncol 2014;19:570-8. https://doi.org/10.1007/s10147-014-0717-z
- Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: longterm results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol 2010;28:1106-11. https://doi.org/10.1200/JCO.2009.25.8475
- Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:67-74. https://doi.org/10.1016/j.ijrobp.2007.06.054
피인용 문헌
- Optimal collimator rotation based on the outline of multiple brain targets in VMAT vol.13, pp.None, 2017, https://doi.org/10.1186/s13014-018-1039-5
- Stereotactic Radiosurgery for Prostate Cancer Following Magnetic Resonance Imaging Directed Biopsy: A Multidisciplinary Approach with Case Examples vol.10, pp.4, 2018, https://doi.org/10.7759/cureus.2524
- SBRT for Localized Prostate Cancer: Is it Ready for Take-Off? vol.105, pp.3, 2019, https://doi.org/10.1016/j.ijrobp.2019.07.008